Citations

Showing 10 of 108083 citations.

Upregulation of Neuronal VEGF in Experimental Cerebral Malaria Coincides with Disease Severity Biomarkers in Humans: A Novel Mechanism of Pathophysiology
Johnson, Aaron J., Fain, Cori E. , Rana, Sabhya , Sieck, Gary C. , Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 190.19-190.19

10.4049/jimmunol.202.supp.190.19 Get It

Abstract Cerebral malaria (CM) is a deadly neurological complication of Plasmodium falciparum infection resulting in high mortality or severe cognitive deficit. Current therapeutics are highly ineffective, namely due to drug resistance and lack of mechanistic insight into pathophysiology. CM is characterized by VEGF upregulation, disruption of blood-brain barrier (BBB), vascular permeability, and severe edema detectable by MRI. Using small animal MRI and the established animal model of CM Plasmodium berghei ANKA, we recapitulate these features of human disease. Here we show that regions of brain permeability during CM as identified by T1-weighted gadolinium-enhanced and T2-weighted MRI coincide with VEGF mRNA upregulation. Regions of analysis include granular and glomerular cell layers of main olfactory bulb and superior medullary brainstem. We determined through RNA in situ hybridization that neurons are the major cell type responsible for the increased VEGF production during CM. Interestingly, we identified another cell type found to minimally upregulate VEGF in close proximity to these neurons. These VEGF expressing cells may play a role in support or induction of the neuronal response. Intriguingly, astrocytes show no VEGF upregulation during this pathology. Overall, these findings suggest a novel role for neuronal-VEGF in promoting CNS pathology, and a putative mechanism of BBB disruption and vascular permeability during CM.
Brain-Thymus communication is a novel immunosuppressive feature of neurological insults
Khadka, Roman H., Jin, Fang, Johnson, Aaron J., Ayasoufi, Katayoun , Pfaller, Christian K. , Jin, Fang, Johnson, Aaron J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 183.19-183.19

10.4049/jimmunol.202.supp.183.19 Get It

Abstract Systemic immunosuppression following neurological insults including stroke, traumatic brain injury, and glioblastoma mutiforme (GBM) causes mortality and leads to failure of therapies. Exact immunological nature and the underlying mechanisms of this immunosuppression are unknown. Our goal was to define effects of neurological insults given exclusively to the brain on the thymus; a primary immune organ. Specifically, we evaluated the effects on the thymus following physical injury with intracranial PBS injection, intracranial (ic) Theiler’s Murine Encephalomyelitis Virus infection, intracranial injection with lipopolysaccharide, CNS tumors (B16 melanoma and GL261 glioma ic), and seizure induction with intraperitoneal Kainic acid injection. These insults resulted in significant thymic involution that is reversible upon clearance of the neurological insult. The extent of thymic involution correlated with the extent of brain injury. Further analysis of the brain-thymus axis in mice with GL261 gliomas was conducted using RNA-Seq. Principle component analysis of RNA-Seq data revealed unbiased separation of thymi of naïve and glioma harboring mice, suggesting that thymus is directly affected by brain injury. To determine the extent to which thymic involution was caused by a soluble factor, we employed parabiosis. This approach demonstrated a soluble factor is responsible for thymic involution. These findings are the first demonstration that neurological insults ubiquitously contribute to immune suppression. We also provide evidence that thymic involution is mediated by a soluble factor, the identification of which could be critical for ameliorating the effect of neurological injuries on immune suppression.
Inducible nitric oxide synthase (iNOS) mediated inhibition of T cell receptor (TCR) signaling is a mechanism for eosinophil dependent amelioration of alloimmunity in lung grafts
Onyema, Oscar Okwudiri , Guo, Yizhan, Mahgoub, Bayan , Manafi, Amir , Criswell, Stacey J , Kreisel, Daniel , Krupnick, Alexander S. , Lannigan, Joanne , Jacobsen, Elizabeth A. , Gelman, Andrew E

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 69.9-69.9

10.4049/jimmunol.202.supp.69.9 Get It

Abstract Eosinophils play a surprising role in downregulating lung graft-specific alloimmunity, even without immunosuppression. We demonstrate here, a mechanism used by eosinophils to downregulate alloimmune responses. To study the mechanism of eosinophil dependent downregulation of alloimmune responses, we used a model of diphtheria toxin (DT) dependent ablation of eosinophils in iPHIL, a mouse model expressing DT receptor on the eosinophil-peroxidase gene locus. Fully MHC-mismatched Balb/c (H2Kd) lungs were engrafted to iPHIL (H2Kb) recipients without immunosuppression. We modeled alloreactivity in vitro, with mixed leukocyte cultures, comprising Th1-polarized eosinophils as modulators of T cells from C57BL/6J or Nur77-GFP mice stimulated by either allogeneic dendritic cells or anti-CD3/CD28 agonistic antibodies. Ablation of eosinophils in non-immunosuppressed lung graft recipients leads to enhanced T cell activation and graft rejection. Similarly, in vitro, we observed a dose and contact dependent downregulation of T cell activation by eosinophils. While contact between eosinophils and T cells is mediated through the upregulation of PD-L1 on both wild-type and iNOS−/− eosinophils after TH-1 polarization, the inhibition of T cell activation is iNOS dependent and is directly linked to the iNOS dependent inhibition of the TCR signaling early gene, Nr4a1, monitored in Nur77-GFP mice. Thus, following contact with T cells, iNOS-expressing eosinophils downregulate lung graft alloimmunity through a direct effect on TCR engagement early genes, leading to the inhibition of T cell activation. This provides an explanation for the surprising observation of lung-graft specific alloimmune downregulation by eosinophils.
ST8Sia6 generated α2,8-disialic acids mitigate hyperglycemia in multiple low dose streptozocin-induced diabetes
Belmonte, Paul , Shapiro, Michael J. , McCue, Shaylene , Rajcula, Matthew, Shapiro, Michael, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 68.16-68.16

10.4049/jimmunol.202.supp.68.16 Get It

Abstract Type 1 diabetes is an autoimmune disease that destroys insulin-producing beta cells in the pancreatic islets. Although exogenous insulin replacement therapy is lifesaving, precise blood glucose management remains a significant challenge. Experimental islet transplantation restores normoglycemia, but the lack of available islets and graft rejection present major barriers to widespread adoption as standard therapy. The islet resident macrophage (IRM) is in close contact with beta cells, efficiently presents islet antigen to autoreactive T cells, and is critical to disease occurrence. We have demonstrated that murine IRMs express high levels of Siglec-E, an immune-regulatory receptor that preferentially binds α2,8-disialic acids in cis or in trans. When islets were exposed to streptozocin (STZ)-induced stress in culture, beta cells upregulated ligands for Siglec-E. To determine the biological significance of this, we generated a mouse model where ST8Sia6, the sialyltransferase that produces α2,8-disialic acids and thus Siglec-E ligands, is constitutively overexpressed in beta cells. This increased trans Siglec-E binding affinity to the beta cell surface, and mitigated hyperglycemia in the multiple low-dose STZ model of diabetes. Significant reduction in blood sugar was evident at 14 days post-initial injection of STZ, coinciding with T cell infiltration of islets. T cells from ST8Sia6+ islets were less activated when compared to littermates. This work reveals a novel and important role for Siglec-E in autoimmune diabetes and provides insight into how rational targeting of this immune receptor may instruct islet-residing antigen presenting cells to provide local tolerance signals in the setting of islet transplantation.
Single-cell RNA-seq of young and aged alveolar macrophages
Wu, Yue , Zhu, Bibo, Goplen, Nick G., Zhang, Ruixuan, Cardani, Amber, Braciale, Thomas J. , Sun, Jie , Li, Ying , Sun, Jie

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 129.18-129.18

10.4049/jimmunol.202.supp.129.18 Get It

Abstract Alveolar Macrophages (AMs) are a unique population of innate immune cells that reside in the alveolar space and contribute to accommodate the ever-changing need of the lungs against the external environmental challenges. AMs derive from the fetal origins and are capable of maintaining themselves through self-renewal without the input of hematopoiesis during the adulthood. However, little is known about how aging is influencing the molecular characteristics and heterogeneity of the AMs during homeostasis. Using single-cell RNA sequencing (scRNA-seq) and Seurat clustering, we discovered AMs can be subdivided into different “subsets” with unique molecular characteristics during homeostasis. Interestingly, when we further investigate the AM population with the combined data from the young(~8w) and old(~2y) mice, the data suggested that the proliferating cell fall in the same cluster with reduced number in the old-mice group, while the poised inflammatory cells showed distinct molecular patterns between the group with different age. We hypothesize that the inflammatory and the self-renewal AM subpopulations may be maintained by distinct extracellular signals. With the progress of aging, the self-renewal ability of AMs would reduce because of the number of proliferating cells but not the change of molecular patterns. At the same time, the inflammatory population would change its characteristics with age, and potentially lead to functional change upon activation. Further validation of the AM subset identity as well as the developmental and functional interrelationship of these subsets are required. In addition, the extrinsic and intrinsic signals responsible for the maintenance of these AM subsets are to be explored.
Does IgE Bind to and Activate Eosinophils from Patients with Allergy?
Kita, Hirohito , Weiler, Deborah A., Schimming, Andrew W., Reed, Charles E., Gleich, Gerald J. , Kita, H , Kaneko, Masayuki, Bartemes, Kathleen R.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 162 | Issue: 11 | Pages: 6901-6911

10.4049/jimmunol.162.11.6901 Get It

Abstract Human eosinophils have been reported to express both the mRNA and protein for the high affinity IgE receptor (FcεRI); it is speculated that this receptor plays a role in eosinophil mediator release in allergic diseases. However, questions still remain. How much of the FcεRI protein is actually expressed on the cell surface of the eosinophil? If they are present, are these IgE receptors associated with effector functions of eosinophils? To address these issues, we studied blood eosinophils from patients with ragweed hay fever. A high level of low affinity IgG receptor (FcγRII, CD32), but no expression of FcεRI, was detectable on the eosinophil surface by standard FACS analysis. However, after in vitro sensitization with biotinylated chimeric IgE (cIgE), cell-bound cIgE was detected by PE-conjugated streptavidin. This cIgE binding was partially inhibited by anti-FcεRI mAb, suggesting that eosinophils do express minimal amounts of FcεRI detectable only by a sensitive method. Indeed, FACS analysis of whole blood showed that eosinophils express ∼0.5% of the FcεRI that basophils express. When stimulated with human IgE or anti-human IgE, these eosinophils did not exert effector functions; there was neither production of leukotriene C4 or superoxide anion nor any detectable degranulation response. In contrast, eosinophils possessed membrane-bound human IgG and showed functional responses when stimulated with human IgG or anti-human IgG. Thus, IgG and/or cytokines, such as IL-5, appear to be more important for eosinophil activation in allergic diseases than IgE.
Modulation of CD28 Expression: Distinct Regulatory Pathways During Activation and Replicative Senescence
Vallejo, Abbe N. , Weyand, Cornelia M. , Brandes, Johann Christoph , Goronzy, Jörg J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 162 | Issue: 11 | Pages: 6572-6579

10.4049/jimmunol.162.11.6572 Get It

Abstract The costimulatory molecule CD28 has a restricted tissue distribution and is expressed on T cells and some plasmacytoma cells. Although CD28 is constitutively expressed, its expression is transiently down-regulated following T cell activation and declines progressively with in vitro senescence. In vivo, CD8+ T cells and, less frequently, CD4+ T cells may completely lose CD28 surface expression during chronic infections and with aging. This correlates with changes of nuclear protein-binding activities to two motifs, site α and β, within the CD28 minimal promoter. Both α- and β-bound complexes are found only in lymphoid tissues, in CD28+ T cells, and in some transformed B cells. These complexes are coordinately expressed except during replicative senescence, which is characterized by the down-modulation of site β- but not site α-binding activities. In contrast, T cell activation induces a parallel decline in both site α- and β-binding activities. CD4+ and CD8+ T cells differ in their β-binding profiles, which may explain the more pronounced down-regulation of CD28 in senescent CD8+ T cells. In vivo expanded CD4+CD28null and CD8+CD28null T cells uniformly lack α- and β-bound complexes, resembling the pattern seen in chronically activated cells and not of senescent cells.
Inhibition of effective anti-tumor immunity by macrophage Bcl6
Desai, Nidhi Nitin, ZHU, BIBO, Son, Youngmin , Sun, Jie , Sun, Jie

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 135.28-135.28

10.4049/jimmunol.202.supp.135.28 Get It

Abstract The role of Bcl6 expression in different immune compartments in regulating anti-tumor immunity is relatively unknown. Previous studies have linked Bcl6 expression in PBMC with poor prognosis in non-small cell lung cancer. We found that high expression of Bcl6 in tumor predicts survival in gastric and ovarian cancers. Using cell type specific conditional knockouts, we were able to investigate the contribution of Bcl6 expression in different lineages in modulating immune response to subcutaneously implanted B16-ova melanoma tumors. Myeloid deficiency of Bcl6 results in decreased tumor growth and metastasis. This is accompanied by enrichment of antigen specific T cells within the tumor. These tumor infiltrating T cells show an increased expression of exhausted markers such as PD-1, Lag-3 and Tim-3. Tumor associated innate cells also upregulate PD-L1. Furthermore, the TILs display an enhanced effector profile measured by robust production of granzyme B, interferon gamma and CCL3 on ex vivo stimulation. This is accompanied by increase in poly-functional CD8 T cells. Our result suggests that Bcl6 expression in the monocyte/macrophage lineage dampens the development of effective anti-tumor immunity and augments immunosuppressive tumor microenvironment. We will elucidate the exact underlying mechanisms and evaluate the translational potential of Bcl6 inhibitors in conjunction with immune checkpoint blockade in the future.
ST8Sia6 Overexpression Accelerates Tumor Growth, Alters Macrophage Polarization and the Immune Response
Shapiro, Michael J. , Rajcula, Matthew, McCue, Shaylene , Friedman, David J. , Shapiro, Michael, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 135.8-135.8

10.4049/jimmunol.202.supp.135.8 Get It

Abstract T-cell targeted immunotherapy has resulted in novel treatments for multiple cancers and has been the primary focus in cancer immunotherapy. However, many patients still fail checkpoint therapies due to immune suppression mechanisms driven by cells, such as tolerogenic M2-like macrophages, which support tumor growth. ST8Sia6, a sialyltransferase, generates α2,8-linked disialic acids on O-linked glycoproteins. Cancer patients with high ST8Sia6 expression exhibit reduced survival as compared to patients with low expression, but the mechanism is unknown. We generated MC38 and B16–F10 murine cancer cell lines that overexpress ST8Sia6. Expression of ST8Sia6 accelerated flank tumor growth in both single and dual flank injection models as compared to parental tumors. In vivo, macrophage polarization was altered in ST8Sia6 expressing tumors. At day 7, tumor associated macrophages (TAMs) from ST8Sia6 negative MC38 tumors were primarily M1-like, while TAMs from ST8Sia6 expressing MC38 tumors were predominately M2-like. Tumor growth and M2-like polarization was dependent Siglec-E. Siglec-E present on innate cells bind α2,8-linked disialic acids generated by ST8Sia6 and suppress immune activation. Therefore, ST8Sia6 overexpressing tumors engage Siglec-E, suppressing the immune response and increasing tumor growth. ST8Sia6 overexpression in a spontaneous murine colon cancer model decreased survival from over 6 months to 2–3 months. Therefore, ST8Sia6 expression in tumors may promote tumor growth by promoting tolerogenic immune responses.
Runx1 is a key regulator of T cell anergy
Wilfahrt, Drew Nicholas, Hsu, Fan‐Chi , McCue, Shaylene , Rajcula, Matthew, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 56.15-56.15

10.4049/jimmunol.202.supp.56.15 Get It

Abstract The transcription factor Runx1 is critical for T cell development and maturation. CD4-Cre Runx1 conditional knockout mice have a block in T cell maturation, leading to complement deposition on recent thymic emigrants, and leaving very few CD4+T cells in peripheral lymphoid organs. Interestingly, thymic- and splenic-derived T cells from CD4-Cre Runx1 cKO mice exhibit increased expression of markers indicative of anergy including FR4 and CD73, which is not seen in other genetically modified mice with a block in T cell maturation. These data suggest Runx1 plays a role in regulating the development of T cell anergy in CD4+T cells. We have generated a 1:1 mixed bone marrow chimera (BMC) system with Estrogen Receptor-Cre (ER-Cre) Runx1 conditional knockout and wild type B6.SJL bone marrow to delete Runx1 in mature CD4+ T cells. Upon tamoxifen treatment and deletion of Runx1, the ER-Cre Runx1 cKO CD4+ T cells spontaneously develop an anergic phenotype as they fail to proliferate upon TCR/CD28 stimulation, and co-express CD73 and FR4. This cell surface phenotype is cell intrinsic since wild type B6.SJL CD4+ T cells in the mixed bone marrow chimera do not upregulate CD73 and FR4 upon tamoxifen treatment. Surprisingly, the mixed BMC system reveals both the ER-Cre Runx1 cKO and the wild type B6.SJL peripheral T cells fail to proliferate in response to TCR/CD28 stimulation, suggesting Runx1 also regulates a cell-extrinsic suppressive mechanism controlling T cell tolerance. This cell-extrinsic induction of anergy requires Runx1-deficient CD4+ T cells, but it is not dependent on Runx1-deficient Tregs. Thus, Runx1 is a key regulator of T cell anergy, and further analysis of this BMC model will serve to uncover the mechanism.